Prognostic factors in multiple myeloma in a population-based trial.
Prognostic factors have been tested in patients with multiple myeloma treated according to a randomized trial of standard therapy versus 5-drug combination therapy. The following population-based study included 92 patients with a median age of 70 yr. The median survival was 31 months. The Cox regression model was used to search for predictors of survival. The cut-off levels for blood analyses derived in earlier studies tended to select few patients in the high-risk groups, for example only 8% of the patients had hemoglobin (Hb) less than or equal to 7.5 g/dl. Lytic bone lesions in the pelvis or in the long bones, or spontaneous fractures and age greater than 70 yr gave prognostic information in addition to anemia and impaired renal function. The MRC staging system was a better prognostic tool than the Durie & Salmon stages. Palliative treatment regimens which take quality of life into account should be considered carefully in multiple myeloma patients greater than 70 yr.
Hannisdal
E
E
Norwegian Radium Hospital, Harstad Hospital, Trondheim.
Kildahl-Andersen
O
O
Grøttum
K A
KA
Lamvik
J
J
D000368:Aged; D000375:Aging; D000740:Anemia / Q000150:complications; D001847:Bone Diseases / Q000150:complications; D001842:Bone and Bones / Q000293:injuries; D002118:Calcium / Q000097:blood; D003404:Creatinine / Q000097:blood; D004359:Drug Therapy, Combination; D050723:Fractures, Bone; D006801:Humans; D007674:Kidney Diseases / Q000150:complications; D009101:Multiple Myeloma / Q000150:complications / Q000188:drug therapy / Q000401:mortality*; D010384:Pelvic Bones / Q000293:injuries; D011379:Prognosis; D015996:Survival Rate
D003404:Creatinine; D002118:Calcium